Tag Archives: Picture Based Assessments

National Screening for Dementia Not Recommended (UK NSC / AHRQ / Annals of Internal Medicine / Epidemiology / International Journal of Epidemiology)

Posted on January 19, 2015 by Dementia and Elderly Care News

Summary The UK National Screening Committee (UK NSC) has upheld previous recommendations against screening people aged 65 and over for dementia. This decision follows an extensive review of the evidence. The UK NSC has concluded that tests for dementia, which … Continue reading →

Posted in Acute Hospitals, Community Care, Department of Health, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Guidelines, Models of Dementia Care, National, NHS, Patient Care Pathway, Person-Centred Care, Practical Advice, Public Health England, Quick Insights, Standards, UK, Universal Interest | Tagged (Hepatocellular Carcinoma: Alphafetoprotein), Activities of Daily Living (ADL), Activities of Daily Living Scale, ADAS-Cog, ADAS-Cog: Alzheimer’s Disease Assessment Scale - Cognitive Subscale, Addenbrooke's Cognitive Examination (ACE), Addenbrooke's Cognitive Examination-Revised (ACE-R), Alzheimer's Disease Assessment Scale (ADAS-Cog11), Alzheimer’s Early Screening, Annals of Internal Medicine, Australia, Benefits of Detection and Early Intervention, Best Interest Decisions, Best Interests, Best Interests of Patients, Blackfriars Consensus Statement, Bond University, Brief Assessments, Cambridge Cognitive Examination (CAMCOG), CAMCOG-R: Cambridge Cognitive Examination-Revised, Case Finding, Case Finding for Patients with Dementia, Centre for Research in Evidence-Based Practice: Bond University, CERAD-NP, Clock Drawing Test, Clock Drawing Test (CDT), Cognition Disorders, Cognitive Assessment Tools, Cognitive Impairment, Complex Best Interests Decision Making, Consortium to Establish a Registry for Alzheimer’s Disease – NP (CERAD-NP), Counter-Intuitive Screening Evidence, Counterintuitive Screening Evidence, Dementia Case Finding, Dementia Case Finding Scheme, Dementia Challenge, Dementia Diagnosis, Dementia Screening, Dementia Screening Debate, DemTect, Department of Medicine: Stanford University School of Medicine, Department of Statistics: Stanford University School of Humanities and Sciences, Diagnosis and Referral, Diagnosis and Support, Diagnosis Gap, Diagnosis of Dementia, Diagnosis Rates, Difficult Conversations, Doctor-Patient Relationships, Dr Anne Mackie: Director of Programmes (UK NSC), Dr Charles Alessi: Dementia Lead for PHE, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Screening, Effectiveness of Early Detection and Treatment, Ethical Considerations, Ethical Dilemmas, Ethical Issues of Dementia Care, Ethics and Decision-Making, General Practice, GPs, Harms of Detection and Early Intervention or Treatment, Improving Diagnosis, Incentive Payments, International Journal of Epidemiology, International Journal of Geriatric Psychiatry, Mass Screening, MCI: Mild Cognitive Impairment, Memory Assessments, Mild Cognitive Impairment, Mild Cognitive Impairment (MCI), Montreal Cognitive Assessment (MoCA), Neuropsychological Tests, olutions for Public Health (SPH), Opinions About Meaning of Overdiagnosis: National Community Survey of Australians, PHE: Public Health England, Picture Based Assessments, Population Screening for Dementia Deyond Passive Case-Finding, Post-Diagnosis Support, Pre-Dementia (MCI), Prevalence of Cognitive Impairment, Primary Prevention Interventions, Prime Minister's Challenge on Dementia, Prime Minister’s Dementia Challenge, Progression of Mild Cognitive Impairment to Dementia, Quality Premium Payments, Recommendation against national dementia screening. London: Public Health England (PHE), Risk Assessment, Risk of Overdiagnosis Associated With Screening, Rowland Universal Dementia Assessment Scale (RUDAS), School of Public Health: University of Sydney, Screening, Screening for Cognitive Impairment, Screening for Cognitive Impairment in Older Adults, Screening for Dementia, Screening Programmes, Screening Tests, Screening: Counter-Intuitive Evidence, Screening: Counter-Intuitive Evidence (Abdominal Aortic Aneurysm), Screening: Counter-Intuitive Evidence (Abdominal Aortic Aneurysm: Ultrasound), Screening: Counter-Intuitive Evidence (Breast Cancer), Screening: Counter-Intuitive Evidence (Breast Cancer: Breast Self-Exam), Screening: Counter-Intuitive Evidence (Breast Cancer: Clinical Breast Exam), Screening: Counter-Intuitive Evidence (Breast Cancer: Mammography), Screening: Counter-Intuitive Evidence (Cardiovascular Disease), Screening: Counter-Intuitive Evidence (Cardiovascular Disease: Echocardiography), Screening: Counter-Intuitive Evidence (Cervical Cancer), Screening: Counter-Intuitive Evidence (Cervical Cancer: Cytology), Screening: Counter-Intuitive Evidence (Cervical Cancer: Human Papilloma Virus), Screening: Counter-Intuitive Evidence (Cervical Cancer: Visual Inspection), Screening: Counter-Intuitive Evidence (Colorectal Cancer), Screening: Counter-Intuitive Evidence (Colorectal Cancer: Faecal Occult Blood Test [FOBT]), Screening: Counter-Intuitive Evidence (Colorectal Cancer: Fecal Occult Blood Test [FOBT]), Screening: Counter-Intuitive Evidence (Colorectal Cancer: Flexible Sigmoidoscopy With or Without FOBT), Screening: Counter-Intuitive Evidence (Colorectal Cancer: Flexible Sigmoidoscopy), Screening: Counter-Intuitive Evidence (Colorectal Cancer: Single Flexible Sigmoidoscopy), Screening: Counter-Intuitive Evidence (Hepatocellular Carcinoma), Screening: Counter-Intuitive Evidence (Hepatocellular Carcinoma: Alphafetoprotein and Ultrasound), Screening: Counter-Intuitive Evidence (Lung Cancer), Screening: Counter-Intuitive Evidence (Lung Cancer: CA-125), Screening: Counter-Intuitive Evidence (Lung Cancer: Chest X-Ray), Screening: Counter-Intuitive Evidence (Lung Cancer: Chest X-Ray and Cytology), Screening: Counter-Intuitive Evidence (Lung Cancer: CT Scan), Screening: Counter-Intuitive Evidence (Multiple Flexible Sigmoidoscopy), Screening: Counter-Intuitive Evidence (Oral Cancer), Screening: Counter-Intuitive Evidence (Oral Cancer: Visual Exam), Screening: Counter-Intuitive Evidence (Ovarian Cancer), Screening: Counter-Intuitive Evidence (Ovarian Cancer: CA–125), Screening: Counter-Intuitive Evidence (Prostate Cancer), Screening: Counter-Intuitive Evidence (Prostate Cancer: Prostate-Specific-Antigen), Screening: Counter-Intuitive Evidence (Type 2 Diabetes), Screening: Counter-Intuitive Evidence (Type 2 Diabetes: Fasting Blood Glucose and HbA1c), Solutions for Public Health (SPH) Review, Stanford Prevention Research Center: Stanford University School of Medicine, Stanford University School of Medicine, Systematic Population Dementia Screening Programme: Not Recommended (UK NSC), Target Culture, Target-Driven Behaviour, Target-Driven Priorities, Targeted Screening, Timely Diagnosis, Trail Making Assessments, Trail Making Test, Trail Making Tests, Transition from Cognitive Impairment to Dementia, U.S. Preventive Services Task Force (USPSTF), UK National Screening Committee, UK National Screening Committee (UK NSC), United States Preventive Services Task Force, United States Preventive Services Task Force (USPSTF), University of Sydney, USA Department of Health Research and Policy, USA Department of Health Research and Policy: Stanford University School of Medicine, Verbal Fluency, Verbal Fluency Assessments | Leave a comment